Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy

Fig. 4

Expansion and persistence of CAR-T cells after CART2. A CAR-T copy number in PB detected by qPCR. B Transgenic copy number of each component of the CART2 treatment: CD19 and CD22 CAR-T cells in pt04. C In pt05, the vector copy number at 89 days after CART2 was higher than at 60 days after CART1. D Pt05 continued to be in a state of B-cell aplasia after CART2, which was reflected by the proportion of CD19+ B cells (%) and the absolute number of B cells (cells/μL). E Changes in the ratio of CD4/CD8 T or CAR-T cells around CAR-T infusion

Back to article page